Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2021 Oct 28

PMID 34707776

Citations 81

Authors

Javad Sharifi-Rad

Cristina Quispe

Jayanta Kumar Patra

Yengkhom Disco Singh

Manasa Kumar Panda

Gitishree Das

Charles Oluwaseun Adetunji

Olugbenga Samuel Michael

Oksana Sytar

Letizia Polito

Jelena Zivkovic

Natalia Cruz-Martins

Marta Klimek-Szczykutowicz

Halina Ekiert

Muhammad Iqbal Choudhary

Seyed Abdulmajid Ayatollahi

Bekzat Tynybekov

Farzad Kobarfard

Ana Covilca Muntean

Ioana Grozea

Sevgi Durna Dastan

Monica Butnariu

Agnieszka Szopa

Daniela Calina

Affiliations

Soon will be listed here.

Abstract

Paclitaxel is a broad-spectrum anticancer compound, which was derived mainly from a medicinal plant, in particular, from the bark of the yew tree Nutt. It is a representative of a class of diterpene taxanes, which are nowadays used as the most common chemotherapeutic agent against many forms of cancer. It possesses scientifically proven anticancer activity against, e.g., ovarian, lung, and breast cancers. The application of this compound is difficult because of limited solubility, recrystalization upon dilution, and cosolvent-induced toxicity. In these cases, nanotechnology and nanoparticles provide certain advantages such as increased drug half-life, lowered toxicity, and specific and selective delivery over free drugs. Nanodrugs possess the capability to buildup in the tissue which might be linked to enhanced permeability and retention as well as enhanced antitumour influence possessing minimal toxicity in normal tissues. This article presents information about paclitaxel, its chemical structure, formulations, mechanism of action, and toxicity. Attention is drawn on nanotechnology, the usefulness of nanoparticles containing paclitaxel, its opportunities, and also future perspective. This review article is aimed at summarizing the current state of continuous pharmaceutical development and employment of nanotechnology in the enhancement of the pharmacokinetic and pharmacodynamic features of paclitaxel as a chemotherapeutic agent.

Citing Articles

Synergistic Nanoformulation: Streamlined One-Pot Synthesis Enhances Paclitaxel Functionalization Gold Nanoparticles for Potent Anticancer Activity.

Velhal K, Sah P, Naik H, Raut R, Patil S, Yamgar R Cell Biochem Biophys. 2025; .

PMID: 40011315 DOI: 10.1007/s12013-025-01701-w.

Evaluation of Bioactivity of Essential Oils: Cytotoxic/Genotoxic Effects on Colorectal Cancer Cell Lines, Antibacterial Activity, and Survival of Lactic Acid Bacteria.

Kozics K, Mesarosova M, Sramkova M, Buckova M, Puskarova A, Galova D Molecules. 2025; 30(4).

PMID: 40005205 PMC: 11858314. DOI: 10.3390/molecules30040890.

Current Paradigms and Future Challenges in Harnessing Nanocellulose for Advanced Applications in Tissue Engineering: A Critical State-of-the-Art Review for Biomedicine.

Dar M, Xie R, Liu J, Ali S, Pawar K, Sudiana I Int J Mol Sci. 2025; 26(4).

PMID: 40003914 PMC: 11855852. DOI: 10.3390/ijms26041449.

Phyto-chemistry and Therapeutic Potential of Natural Flavonoid Naringin: A Consolidated Review.

Anush Sheikh K, Haokip S, Hazarika B, Devi O, Lian H, Yumkhaibam T Chin J Integr Med. 2025; .

PMID: 39994136 DOI: 10.1007/s11655-025-3826-9.

Advancing triple-negative breast cancer treatment through peptide decorated solid lipid nanoparticles for paclitaxel delivery.

Rahdari T, Mahdavimehr M, Ghafouri H, Ramezanpour S, Ehtesham S, Asghari S Sci Rep. 2025; 15(1):6043.

PMID: 39972039 PMC: 11840053. DOI: 10.1038/s41598-025-90107-y.

References

Carter P . Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2002; 1(2):118-29. DOI: 10.1038/35101072. View

Manfredi J, Horwitz S . Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther. 1984; 25(1):83-125. DOI: 10.1016/0163-7258(84)90025-1. View

Shifrin N, Raulet D, Ardolino M . NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol. 2014; 26(2):138-44. PMC: 3984600. DOI: 10.1016/j.smim.2014.02.007. View

Chen Z, Wang C, Li T, Li K, Yue Y, Liu X . Doxorubicin conjugated with nanodiamonds and in free form commit glioblastoma cells to heterodromous fates. Nanomedicine (Lond). 2019; 14(3):335-351. DOI: 10.2217/nnm-2018-0330. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Lam A, Bert N, Ho S, Shen Y, Tang L, Xiong G . RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma. Cancer Res. 2014; 74(8):2193-2203. PMC: 4229084. DOI: 10.1158/0008-5472.CAN-13-1703. View

Albrengues J, Shields M, Ng D, Park C, Ambrico A, Poindexter M . Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018; 361(6409). PMC: 6777850. DOI: 10.1126/science.aao4227. View

Fornier M, Risio M, Van Poznak C, Seidman A . HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park). 2002; 16(10):1340-8, 1351-2; discussion 1352, 1355-8. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

10.

Bhatt R, Merchan J, Parker R, Wu H, Zhang L, Seery V . A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer. 2010; 116(7):1751-6. PMC: 2847062. DOI: 10.1002/cncr.24902. View

11.

Ma P, Mumper R . Paclitaxel Nano-Delivery Systems: A Comprehensive Review. J Nanomed Nanotechnol. 2013; 4(2):1000164. PMC: 3806207. DOI: 10.4172/2157-7439.1000164. View

12.

Greten F, Eckmann L, Greten T, Park J, Li Z, Egan L . IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118(3):285-96. DOI: 10.1016/j.cell.2004.07.013. View

13.

DIncalci M, Badri N, Galmarini C, Allavena P . Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014; 111(4):646-50. PMC: 4134488. DOI: 10.1038/bjc.2014.149. View

14.

Kampan N, Madondo M, McNally O, Quinn M, Plebanski M . Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int. 2015; 2015:413076. PMC: 4475536. DOI: 10.1155/2015/413076. View

15.

Klauber N, Parangi S, Flynn E, Hamel E, DAmato R . Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997; 57(1):81-6. View

16.

Walsh V, Goodman J . From taxol to Taxol: the changing identities and ownership of an anti-cancer drug. Med Anthropol. 2002; 21(3-4):307-36. DOI: 10.1080/01459740214074. View

17.

Zhang D, Yang R, Wang S, Dong Z . Paclitaxel: new uses for an old drug. Drug Des Devel Ther. 2014; 8:279-84. PMC: 3934593. DOI: 10.2147/DDDT.S56801. View

18.

Sharifi-Rad M, Anil Kumar N, Zucca P, Varoni E, Dini L, Panzarini E . Lifestyle, Oxidative Stress, and Antioxidants: Back and Forth in the Pathophysiology of Chronic Diseases. Front Physiol. 2020; 11:694. PMC: 7347016. DOI: 10.3389/fphys.2020.00694. View

19.

Chen Z, Zheng Y, Shi Y, Cui Z . Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles. Int J Nanomedicine. 2018; 13:319-336. PMC: 5768424. DOI: 10.2147/IJN.S149196. View

20.

Wang X, Zhang L, Li X, Kong D, Hu X, Ding X . Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo. Nanomedicine (Lond). 2018; 13(10):1107-1120. PMC: 6219431. DOI: 10.2217/nnm-2017-0355. View